We are interested in the mechanisms that regulate telomere length in normal and cancer cells. Telomeres are the structures at chromosome ends that provide stability to chromosomes and allow the complete replication of the ends. Broken chromosomes that lack telomeres undergo fusions that lead to karyotypic abnormality and chromosome instability; characteristics common in cancer cells. Telomere length is normally maintained as an equilibrium between processes that lengthen and those that shorten telomeres. The ribonucleoprotein DNA polymerase, telomerase, specifically elongates telomeres in vivo. Recent evidence suggests that telomerase may be required for the growth of tumors. Thus, telomerase has been proposed as a new target for cancer chemotherapy. To determine if the absence of telomerase inhibits tumor growth or tumor progression, we are generating a telomerase null mouse in collaboration with Dr. Ronald DePinho. The experiments proposed here will determine whether telomerase is required for tumor induction and for sustained tumor growth. If telomerase is required for sustained tumor growth, tumors lacking telomerase will progress more slowly or perhaps regress, compared to telomerase expressing tumors. Thus or studies in mice will determine whether anti-telomerase drugs may be effective cancer therapeutics. We will look directly for potential recombination mediated telomerase bypass pathways that may lead to telomerase independent tumors. Finally, a telomerase null mouse will help identify potential side effects of telomerase inhibitors, which will need to be addressed in pre-clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA013106-28
Application #
6101503
Study Section
Project Start
1999-01-01
Project End
1999-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
28
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 34:346-348
Skucha, Anna; Ebner, Jessica; Schmöllerl, Johannes et al. (2018) MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nat Commun 9:1983
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 33:527-541.e8
Lin, Kuan-Ting; Ma, Wai Kit; Scharner, Juergen et al. (2018) A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma. Genome Res :
On, Kin Fan; Jaremko, Matt; Stillman, Bruce et al. (2018) A structural view of the initiators for chromosome replication. Curr Opin Struct Biol 53:131-139
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381
Shamay, Yosi; Shah, Janki; I??k, Mehtap et al. (2018) Quantitative self-assembly prediction yields targeted nanomedicines. Nat Mater 17:361-368
Tramentozzi, Elisa; Ferraro, Paola; Hossain, Manzar et al. (2018) The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592. Cell Cycle 17:1102-1114
Arun, Gayatri; Diermeier, Sarah D; Spector, David L (2018) Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med 24:257-277
Tarumoto, Yusuke; Lu, Bin; Somerville, Tim D D et al. (2018) LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. Mol Cell 69:1017-1027.e6

Showing the most recent 10 out of 610 publications